總務室文書組檔案專區

:::

劉嘉仁 (Chia-Jen Liu)

複診掛號初診掛號

[簡介]

學歷
經歷
現職：
經歷：
- - 美國波士頓哈佛醫學院附屬達納法博癌症中心(Dana-Farber Cancer Institute) 博士後研究員
- - 國立陽明交通大學附設醫院內科部主治師
- - 臺北榮民總醫院內科部總醫師
醫療專長
1. 血液學、腫瘤內科學、貧血、惡性淋巴瘤(淋巴癌)、多發性骨髓瘤、急性骨髓性白血病(血癌)、血友病
證照

中華民國腫瘤內科專科醫師、中華民國血液病專科醫師、中華民國血液及骨髓移植專科醫師、中華民國內科專科醫師
語言專長

國語台語英語

[著作]

Manier S¹, Liu CJ¹, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017 Apr;129(17):2429-2436. (IF: 25.476; Hematology 2/78; 2.6%) (co-first author)
Bustoros M¹, Sklavenitis-Pistofidis R¹, Kapoor P¹, Liu CJ¹, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM. Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia. Journal of Clinical Oncology. 2019 Jun; 37(16):1403-1411. (IF: 50.769; Oncology 6/245; 2.4%) (co-first author)
Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. American Journal of Hematology. 2019 Nov; 94(11):1244-1253. (IF: 13.265; Hematology 6/78; 7.7%)
Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS. A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 2020 Jan; 26(2):344-353. (IF: 13.801; Oncology 17/245; 6.9%)
Lai TY, Yeh CM, Hu YW, Liu CJ*. Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy. Radiotherapy and Oncology. 2020 Jul; 151:190-199. (IF: 6.901; Radiology, Nuclear Medicine & Medical Imaging 22/136; 16.2%) (corresponding author)